Editorial draft — not for publication yet. Carisoprodol content needs clinical and legal review before publication. This page is general information and is not advice about an individual prescription.
In short
Carisoprodol is a centrally acting muscle relaxant that was historically used for painful muscle spasm. Its UK marketing authorisations were withdrawn and it is not licensed for routine UK use. A September 2026 draft proposes Class C control, but legal status must be verified against the final legislation and commencement date. Carisoprodol can cause sedation, dependence, withdrawal and potentially fatal overdose, particularly with opioids or benzodiazepines.
Carisoprodol UK status
Carisoprodol is not licensed for routine use in the UK. A draft order proposing Class C control was laid before Parliament on 14 September 2026; as of this source check it is still draft legislation, so check the final law and commencement date before relying on this legal summary.
What was Carisoprodol used for?
Carisoprodol was previously used in the UK for short-term treatment of painful musculoskeletal conditions associated with muscle spasm. It is not licensed for routine UK use now; this historical indication is not a recommendation to take it.
- Historical use as a centrally acting muscle relaxant for painful muscle spasm
- No routine UK licensed indication or standard UK prescribing pathway
- Availability and authorised uses differ between countries; overseas approval does not establish UK authorisation
The European review concluded that the risks of carisoprodol treatment outweighed its benefits. The MHRA highlighted risks including abuse, addiction, intoxication and impaired psychomotor performance.
The ACMD reports dependence, withdrawal and overdose harms, with greater risk when carisoprodol is combined with opioids or benzodiazepines. Do not use online or leftover tablets as a substitute for clinical assessment.
How does it work?
Carisoprodol acts on inhibitory signalling in the central nervous system and is metabolised to meprobamate, an active metabolite with sedative effects. It can reduce muscle-spasm symptoms but also cause drowsiness, impaired coordination and other central nervous system effects. Its former mechanism does not make it an appropriate or available UK treatment.
Risks and possible effects
Reported effects
Drowsiness, sedation, dizziness, headache and impaired coordination have been reported. Effects may be unpredictable with unverified or counterfeit products.
Emergency symptoms
Call 999 for slow or difficult breathing, collapse, seizure, unconsciousness or if someone cannot be woken. Severe toxicity can be life-threatening, especially with opioids or benzodiazepines.
Safety information
- Carisoprodol is not licensed for routine UK use. Do not buy it from an unverified website, use someone else’s medicine or rely on overseas marketing as evidence of UK approval.
- Combining carisoprodol with opioids, benzodiazepines, alcohol or other sedatives can increase sedation and breathing-related overdose risk.
- Prolonged use can lead to dependence. If you have been taking it regularly, speak to a clinician before stopping or substantially reducing it because withdrawal can occur.
- A draft 2026 Order proposes Class C control. Verify current legislation and its commencement date for any legal, possession, travel or import question.
Why UK authorisations were withdrawn
Following a European review, the UK marketing authorisations for carisoprodol were withdrawn because the risks were judged to outweigh the benefits. Safety concerns included abuse, addiction, intoxication and psychomotor impairment. The ACMD later confirmed with the MHRA that carisoprodol remains unlicensed in the UK.
This is different from some other countries where it has been prescribed. An overseas brand or historical UK product name does not mean there is a current routine UK licence.
Proposed UK legal control: check the latest position
The government accepted an ACMD recommendation to add carisoprodol to Class C and Schedule 4 Part 1 when parliamentary time allows. A draft amendment order including carisoprodol was laid before Parliament in September 2026. A draft proposal is not itself proof that the change has come into force.
The final order and its commencement provision should be checked before publication or when answering a personal legal question. This information is dated and is not legal advice.
Dependence, withdrawal and overdose
Prolonged use can cause dependence, and abrupt stopping or a large reduction can trigger withdrawal. Speak with a clinician before making a change if you have been using it regularly.
Carisoprodol can cause severe sedation and breathing depression. Risk is higher with opioids and benzodiazepines. Call 999 if someone cannot be woken, has slow or difficult breathing, collapses or has a seizure.
Frequently asked questions
Is carisoprodol available in the UK?
It is not licensed for routine UK use. The ACMD says the last UK marketing authorisation was cancelled in April 2012.
Is carisoprodol a controlled drug in the UK?
A draft 2026 Order proposes adding carisoprodol to Class C. Check the latest made legislation and commencement date; a draft is not the same as a law in force.
Can carisoprodol cause withdrawal?
Yes. Prolonged use can cause dependence, and abrupt stopping may trigger withdrawal. Get clinical advice before changing regular use.
What should I do if someone is difficult to wake after taking it?
Call 999, particularly if breathing is slow or difficult, or if the person collapses or has a seizure. Do not leave them alone.
Explore the detailed carisoprodol guides
Each guide answers a different practical question. Advice is specific to carisoprodol and should be checked against your own product leaflet and prescription.
- What is carisoprodol? UK medicine status and safety
- Is carisoprodol available in the UK?
- Is carisoprodol legal in the UK? Current status
- What was carisoprodol used for? UK history and risks
- Carisoprodol side effects, impairment and risks
- Carisoprodol dependence and withdrawal: UK guidance
- Carisoprodol interactions with alcohol, opioids and sedatives
- Carisoprodol overdose: symptoms and what to do in the UK
- Carisoprodol and meprobamate: what is the difference?
- Carisoprodol for anxiety? UK status and safer next steps
- Carisoprodol alternatives for muscle spasm in the UK
- Carisoprodol prescribed abroad: UK travel and safety checks
Sources and review
This draft was checked against the sources below on 2 October 2026. It still requires clinical and legal review before publication.
- GOV.UK / ACMD: ACMD review: use, harms and UK status of carisoprodol
- GOV.UK / Home Office: Government response to the ACMD carisoprodol review (3 February 2026)
- legislation.gov.uk: Misuse of Drugs Act 1971 (Amendment) Order 2026 — draft
- UK Parliament: Parliamentary record for the 2026 draft Order
- MHRA / GOV.UK: Carisoprodol and meprobamate: risks outweigh benefits
- MHRA / GOV.UK: Import a human medicine into the UK
- NICE: Low back pain and sciatica in over 16s (NG59)
- NHS: Sprains and strains
Editorial status: Clinical and legal review required before publication.